Graco SEC Filings

The filing is a Form 144 notice indicating the proposed sale of restricted securities in First Trust RiverFront Dynamic Developed International ETF (RFDI). One holder plans to sell 8,000 common shares through broker BTIG LLC on or about 01 July 2025 on the NYSE. At the most recent market price, the transaction is valued at $207,261.60. The shares represent roughly 1.0 % of the 800,002 shares outstanding listed in the notice.

The seller originally acquired a larger block of 100,000 shares on 13 May 2022 via a negotiated private transaction paid in cash. No sales have been made by the filer in the past three months, and the filer affirms no undisclosed material adverse information about the ETF.

Because Form 144 filings are preliminary, the sale may or may not occur, and it is relatively small compared with the ETF’s outstanding units, suggesting limited market impact.

Graco Inc. (GGG) – Form 4 Insider Transaction: On 01 July 2025, director Jody H. Feragen acquired 344.6 deferred stock shares under the company’s Amended & Restated 2019 Stock Incentive Plan. These shares, valued at $85.97 each, were received in lieu of quarterly board retainer fees and are coded “A” (acquired) on the filing. The deferred shares will convert one-for-one into common stock in a lump sum or installments after the director leaves the Board. Following the award, Feragen’s aggregate deferred stock position rose to 12,600.8779 shares, all held directly. The filing is routine compensation-related and exempt under Rule 16a-11.

Graco Inc. (GGG) – Form 4 Insider Transaction Summary

Director Eric Etchart filed a Form 4 reporting the receipt of 286.44 deferred stock shares on 07/01/2025. These shares were granted under the company’s Amended and Restated 2019 Stock Incentive Plan and were taken in lieu of quarterly board retainer fees. The award price reference shown on the form is $85.97 per share. Following the grant, Etchart’s total deferred stock position increased to 16,663.118 shares, all held directly. The deferred shares will convert 100% into Graco common stock and be delivered in a lump-sum or installments when the director leaves the Board. No shares were sold or otherwise disposed of, and the grant is exempt under Rule 16a-11 due to the company’s Automatic Dividend Reinvestment Plan (DRIP).

• Transaction type: Acquisition (deferred stock)
• Shares acquired: 286.44
• Ownership after transaction: 16,663.118 deferred shares (Direct)
• Purpose: Board compensation; not an open-market trade

Graco Inc. (GGG) – Form 4 insider transaction

On 01 July 2025, director Brett C. Carter acquired 72 shares of Graco common stock at an implied price of $85.97 per share. The shares were issued in lieu of the director’s quarterly retainer, rather than an open-market purchase. Following the transaction, Mr. Carter directly owns 3,880.111 shares. No derivative securities or dispositions were reported.

The filing is administrative in nature and reflects routine director compensation through equity instead of cash. The transaction represents a negligible proportion of Graco’s roughly 168 million shares outstanding and is therefore unlikely to have a material impact on valuation or trading dynamics. Nonetheless, electing stock compensation modestly increases director–shareholder alignment.

Inozyme Pharma, Inc. (NASDAQ: INZY) filed Post-Effective Amendment No. 1 to deregister securities remaining under two previously effective shelf Registration Statements on Form S-3 (Nos. 333-258702 and 333-275364). The shelves collectively covered up to $500 million of common stock, preferred stock, debt, depositary shares, subscription rights, warrants and units. As of July 1, 2025, none of the registered securities remain available for sale.

The amendment follows the consummation of Inozyme’s merger with BioMarin Pharmaceutical Inc. Under the Agreement and Plan of Merger dated May 16, 2025, Incline Merger Sub, Inc. merged with and into Inozyme, making Inozyme a wholly-owned subsidiary of BioMarin as of July 1, 2025. Consequently, all outstanding offerings under the shelves were terminated and the company is removing any unsold securities from registration pursuant to its undertaking under Rule 415.

This filing is largely administrative, signaling the formal close-out of Inozyme’s capital-raising capability as a standalone public entity and completing one of the final SEC steps associated with the transaction.

Inozyme Pharma, Inc. (INZY) filed Post-Effective Amendment No. 1 to its two shelf registration statements (Nos. 333-258702 and 333-275364) to deregister all remaining unsold securities, which had allowed for the issuance of up to $500 million of common stock, preferred stock, debt securities and related instruments. The amendment follows the closing of the previously announced merger completed on July 1, 2025, in which Incline Merger Sub, Inc., a wholly-owned subsidiary of BioMarin Pharmaceutical Inc., merged with and into Inozyme, leaving Inozyme as a wholly-owned subsidiary of BioMarin. Because the merger terminates any independent public offering activity, the company is withdrawing the shelves and terminating their effectiveness.